List view / Grid view
Gilead Sciences, Inc. has submitted a NDA to the U.S.…
11 September 2013 | By Gilead Sciences
Gilead Sciences, Inc. has submitted a NDA to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of iNHL...
Gilead Sciences announced that the European Commission has granted marketing…
28 May 2013 | By Gilead Sciences
Gilead Sciences announced that the European Commission has granted marketing authorization for Stribild®...
Gilead Sciences announced that the company’s MAA for sofosbuvir...
21 May 2013 | By Gilead Sciences
Gilead Sciences announced that the company’s MAA for sofosbuvir...
Sofosbuvir, a once-daily oral nucleotide analogue for the treatment of…
8 April 2013 | By Gilead Sciences
Sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection...
Stribild® a once-daily integrase inhibitor-based single tablet regimen for the…
22 March 2013 | By Gilead Sciences
Stribild® a once-daily integrase inhibitor-based single tablet regimen for the treatment of HIV-1 infection...
Gilead Sciences, Inc. announced that the U.S. Food and Drug…
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited…
2 August 2012 | By Gilead Sciences, Inc.
Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into agreements...
Gilead Sciences, Inc. announced that the European Commission has granted…
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
Gilead Sciences, Inc., will acquire Pharmasset, Inc., for $137 per…
21 November 2011 | By Gilead Sciences
Gilead Sciences, Inc., will acquire Pharmasset, Inc., for $137 per share in cash...
CHMP, has adopted a positive opinion on the company's Marketing…
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
A new complete once-daily, single-tablet regimen for HIV-1 infection in…
10 August 2011 | By Gilead Sciences Inc
A new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults...
Gilead Sciences, Inc. is pleased to announce that Kevin Young,…
13 June 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. is pleased to announce that Kevin Young, has been appointed a Commander of The British Empire...
Gilead Sciences, Inc. has extended its funding support of the…
5 May 2011 | By Gilead Sciences, Inc.
Gilead Sciences, Inc. has extended its funding support of the Gilead Sciences Research Centre at the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague...
